270 / 1224
/
C O N C L U S I O N S
Clear dose effect relationship in stage I NSCLC and
pulmonary metastases
Dose explains well high rates of local tumor control
Dose-response not different between primary NSCLC
and pulmonary metastases
PTV encompassing dose >100Gy BED achieves
>90% TCP
Total dose adapted to competing risk of death / distant
progression
Fractionation adapted to risk of OAR toxicity
13.06.2016
Matthias Guckenberger - ESTRO SBRT Course 2016 Athens
28